Bertoni I, Soares MF, Roberts ISD, Connor T. Radiation nephropathy is associated with a glomerular thrombotic microangiopathy and progression to end-stage kidney disease.
Clin Kidney J 2023;
16:1534-1537. [PMID:
37664570 PMCID:
PMC10468744 DOI:
10.1093/ckj/sfad133]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Indexed: 09/05/2023] Open
Abstract
Radiation nephropathy is a rare complication following total body irradiation (TBI) and peptide receptor radionuclide therapy (PRRT). Yttrium 90-DOTATOC (Y90) is a somatostatin analogue labelled with Y90 used for somatostatin-positive neuroendocrine tumours. Y90 is renally excreted and has a cumulative effect in the renal parenchyma Despite fractionation and co-administration of renoprotective intravenous amino acids, targeted radionuclide therapy can still be nephrotoxic. Rising adoption of PRRT has led to the re-emergence of radiation nephropathy. We report on three recent cases of insidious onset of progressive kidney dysfunction and biopsy-proven thrombotic microangiopathy following PRRT and TBI.
Collapse